News

Review top news and interview highlights from the week ending April 11, 2025.

In observance of World Parkinson's Day, held annually on April 11, we took a look back at the past year's news in cell and gene therapy for PD.

The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed the need to bring more innovations from nonclinical research to patients.

The data come from patients treated across 2 studies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed his views on toxicities and costs associated with CAR-T, and when and how the field should address them.

A recent patient death following treatment with the gene therapy raised concerns for the European Medicines Agency.

The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed his view on how the cell therapy field should proceed with regard to innovation.

In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.

The designations apply to lupus, myositis, and scleroderma indications.

The chair of the department of medicine at Roswell Park Comprehensive Cancer Center discussed the innovations necessary to make CAR-T therapy effective in solid tumor indications.

David-Alexandre Gros, MD, the chief executive officer of Eledon Pharmaceuticals, also discussed other future plans for the company.

Alcon noted additional operational updates alongside the announcement.

Review top news and interview highlights from the week ending April 4, 2025.

At 12 weeks posttreatment, all 4 of the patients showed improvement in the form of a lower logMAR.

The move was made in relation to the previously-announced death of a US teenager who received the therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chief executive officer of Eledon Pharmaceuticals also discussed other future plans for the company.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

The product is marketed under the name Qfitlia.

Robert Califf, MD, MACC, a cardiologist and former FDA commissioner, discussed the necessity of policy and funding efforts for neuromuscular disorders, the stress on the clinical care system, and the need to acknowledge healthcare inequities.

Natalie Goedeker, CPNP, the codirector of pediatric neuromuscular clinical research at Washington University in St. Louis, discussed the session she chaired at MDA’s 2025 conference.

David-Alexandre Gros, MD, the chief executive officer of Eledon Pharmaceuticals, discussed the company’s investigational monoclonal antibody and its use along with EGenesis porcine kidney transplant product.

Review top news and interview highlights from the week ending March 28, 2025.

The former FDA commissioner discussed the necessity of policy and funding efforts for neuromuscular disorders, the stress on the clinical care system, and the need to acknowledge healthcare inequities.

The chief executive officer of Eledon Pharmaceuticals discussed the company’s investigational monoclonal antibody and its use along with EGenesis porcine kidney transplant product.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

In pooled data from 156 patients, there were no deaths or study discontinuations.

These findings could support gene therapies targeting CTG18.1 that are currently in development.